PharmD Info

A forum for Indian Pharmacy Professionals

Important: Registered today to have the complete access on this forum --- Register Here
Information for consumers and health professionals on new drug warnings and other safety information, drug label changes, and shortages of medically necessary drug products. Eg: CDCSO,PvPI and FDA Safety Alerts.
  • User avatar
#2260
Health care professionals should, before starting canagliflozin, consider factors that may predispose patients to the need for amputations. These factors include a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Monitor patients receiving canagliflozin for the signs and symptoms described above and discontinue canagliflozin if these complications occur.

Untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. Canagliflozin is a prescription medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Canagliflozin lowers blood sugar by causing the kidneys to remove sugar from the body through the urine.

Final results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus) – showed that leg and foot amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo, which is an inactive treatment. The CANVAS trial showed that over a year’s time, the risk of amputation for patients in the trial were equivalent to:

5.9 out of every 1,000 patients treated with canagliflozin
2.8 out of every 1,000 patients treated with placebo

The CANVAS-R trial showed that over a year’s time, the risk of amputation for patients in the trial were equivalent to:

7.5 out of every 1,000 patients treated with canagliflozin
4.2 out of every 1,000 patients treated with placebo

Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.

We urge health care professionals and patients to report side effects involving canagliflozin.

Drug safety communication Alert 2017- Canagliflozin

https://www.fda.gov/downloads/Drugs/Dru ... 558427.pdf
Similar Topics
Topics Statistics Last post
0 Replies 
743 Views
by Admin
28 Aug 2017, 14:38
41 Replies 
4247 Views
by Sherin
05 Feb 2018, 13:25

Tags

Indian Association of Colleges of Pharmacy. A/C N[…]

PharmD Info Online Group Discussion Disc[…]

PCI chalks out plans to allay concerns of educatio[…]

NAAC is in the process of developing a Manual for […]

WELCOME TO OUR E-LEARN COURSE WORK MODULES